Avantor, Inc. (AVTR) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $8.14: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced technology markets through two segments: Laboratory Solutions (VWR distribution channel) and Bioscience Production (specialty manufacturing). The company... Read more
Sell if holding. Engine safety override at $8.14: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 55. Score 5.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMSuppliersole-sourced raw materials10-K Item 1A: 'many of which are sole-sourced due to market or customer demands'
Material Events(8-K, last 90d)
- 2026-04-01Item 5.02HIGHCFO R. Brent Jones resigned to join a company outside the life sciences industry; 90-day notice required. Steven Eck (SVP, Chief Accounting Officer) named interim CFO pending permanent search. No permanent successor named.SEC filing →
- 2026-04-23Item 5.02MEDIUMBenoit Gourdier (EVP, Bioscience and Medtech Products) transitioning to a supporting role, expected to depart by December 31, 2026. Ludovic Brellier hired as new EVP effective May 1, 2026. Clean handoff with named successor.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -8.4%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.14: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 55. Prior stop was $7.57. Score 5.2/10, moderate confidence.
Take-profit target: $9.20 (+13.0% upside). Prior stop was $7.57. Stop-loss: $7.57.
Quality below floor (3.4 < 4.0).
Avantor, Inc. trades at a P/E of N/A (forward 9.2). TrendMatrix value score: 8.3/10. Verdict: Sell.
25 analysts cover AVTR with a consensus score of 2.8/5. Average price target: $11.
What does Avantor, Inc. do?Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced...
Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced technology markets through two segments: Laboratory Solutions (VWR distribution channel) and Bioscience Production (specialty manufacturing). The company serves more than 300,000 customer locations in approximately 180 countries with more than 85% of net sales from recurring offerings.